Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLT3 CAR_sIL-15 NK cells
- Development stage
- Unknown
- Lead developer
- City of Hope
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FLT3 CAR_sIL-15 NK cells (CYTO-102) is an allogeneic, off-the-shelf natural killer (NK) cell therapy engineered to express a chimeric antigen receptor (CAR) targeting FMS-like tyrosine kinase 3 (FLT3) and to secrete soluble interleukin-15 (sIL-15). Developed by CytoImmune Therapeutics in collaboration with City of Hope, this therapeutic candidate is designed for the treatment of relapsed or refractory acute myeloid leukemia (AML). The integration of sIL-15 is intended to enhance the persistence and metabolic fitness of the NK cells in the immunosuppressive tumor microenvironment and to provide paracrine activation of endogenous T cells and NK cells. The construct incorporates a CD28/CD3ζ costimulatory domain and a truncated EGFR (tEGFR) safety switch, which allows for the rapid depletion of the engineered cells via cetuximab administration if needed. Preclinical studies have demonstrated potent antileukemic activity and improved survival in AML models without significant toxicity to healthy hematopoietic stem cells.
- Other names
- FLT3 CAR-sIL-15 NK cellsFLT-3 CAR-sIL-15 NK cellsFLT 3 CAR-sIL-15 NK cellsFLT3 CAR-sIL-15 NKFLT-3 CAR-sIL-15 NKFLT 3 CAR-sIL-15 NKFLT3 CAR_sIL-15 NK
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on FLT3 CAR_sIL-15 NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLT3 CAR_sIL-15 NK cells.